comparemela.com

Latest Breaking News On - ஸ்காட் கோல் - Page 4 : comparemela.com

Lehigh: Depth and the X-Factor

Andrew Eichelberger’s recruiting visit to Lehigh back in 2014 seems oddly prescient now. When the Texas native came to Bethlehem, a snowstorm delayed the Mountain Hawks’ game, so he had to wait an extra day. He clearly remembers the Kurtis Kaunas’ bouncer that won the game in triple-overtime, but it was his experience off the field that sealed the deal. “The experience with the guys off the field was just as great. All the parents were super inviting and accepting of me and my dad,” he says. “I found my second family out here.” Flash forward to early February 2021, and Eichelberger’s still in Bethlehem as a grad student, and he’s taken on the role of the inviting, mentoring figure to young players. 

ThirdSpace Inc & US Air Force SBIR Partnership

ThirdSpace Inc. & US Air Force SBIR Partnership Share Article MADISON, Wis. (PRWEB) February 19, 2021 ThirdSpace Inc., a SAAS organizational culture platform, today announced a new partnership with the US Air Force through their AFWERX SBIR program. This partnership will explore the cultural and organizational needs of an Air Force unit such as the 115th Fighter Squadron in Madison, WI. The goal is to understand the greatest needs related to airmen wellbeing which may constellate around mental, emotional, spiritual and community factors. ThirdSpace is a malleable framework which may be adapted to solving core cultural problems for the Air Guard. The desire would be to roll out ThirdSpace across the entire guard to be the go to resource in order to amplify the effects of a trusting, safe, and positive culture.

Cabozantinib most effective treatment for metastatic papillary kidney cancer

 E-Mail IMAGE: Sumanta Pal, MD, a SWOG Cancer Research Network researcher and City of Hope physician, led a study that sets a new standard of care for metastatic papillary kidney cancer view more  Credit: City of Hope In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer - findings expected to change medical practice. These findings will be presented at ASCO s virtual 2021 Genitourinary Cancers Symposium on Feb. 13, 2021 at 1 p.m. ET. The findings will be simultaneously published in

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.